Alzheimer’s: drug delivery and the blood brain barrier conundrum
The blood-brain barrier is the biggest hurdle in treating brain diseases, and research on overcoming this challenge is ongoing.
31 July 2024
31 July 2024
The blood-brain barrier is the biggest hurdle in treating brain diseases, and research on overcoming this challenge is ongoing.
The company's revenues saw a slight increase of 2%, amounting to $13.3bn.
Ventyx no longer plans to conduct additional clinical trials of VTX958 with internal resources after the Phase II trial missed its primary endpoint.
This increase in IPO value has set a robust pace for the year, possibly reflecting pent-up demand following the two-year slump in IPO raises.
The European Commission (EC) has approved Vabysmo (faricimab) for the treatment of retinal vein occlusion.
Collegium will pay $525m upfront to add Ironshore’s FDA-approved ADHD medication Jornay to its portfolio.
The fees have increased by around $300,000 from 2024 and by $2m compared to a decade ago.
Semaglutide, marketed as Ozempic and Wegovy, decreased tobacco-related healthcare encounters compared to other medications.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.